FDA-cleared profile

Lunit INSIGHT MMG

Lunit Inc. · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Aid interpreting physicians in detecting, localizing, and characterizing suspicious breast-cancer areas on mammograms from compatible FFDM systems, viewed after the physician completes the initial read.

Clinical role
Second-read adjunct for detection, localization, and characterization; it does not replace complete physician review or clinical judgment.
Images and patients
Mammography/DBT · Breast.
Key limitation
Keep in mind: Use is limited to screening mammograms from compatible FFDM systems and the female screening population described in the packet. The output is adjunctive after the initial read and is not a replacement for complete physician review, clinical judgment, or other patient/image information. DBT is not established in this packet.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Aid interpreting physicians in detecting, localizing, and characterizing suspicious breast-cancer areas on mammograms from compatible FFDM systems, viewed after the physician completes the initial read.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast. Input: Screening mammograms from compatible full-field digital mammography systems, received as DICOM images from a PACS or other radiological imaging equipment.
  • Who uses it?Intended users: Physicians interpreting screening mammograms; the target population is women undergoing FFDM screening mammography.
  • What does the software produce?Output: Visualized lesion maps/heatmaps, finding-level lesion scores from 1-100, and a per-breast abnormality score based on the maximum of the CC and MLO view scores; analysis results are converted to DICOM for storage.
  • What is its most important limitation?Key limitation: Use is limited to screening mammograms from compatible FFDM systems and the female screening population described in the packet. The output is adjunctive after the initial read and is not a replacement for complete physician review, clinical judgment, or other patient/image information. DBT is not established in this packet.

Clinical takeaway. Clinical role: Aid interpreting physicians in detecting, localizing, and characterizing suspicious breast-cancer areas on mammograms from compatible FFDM systems, viewed after the physician completes the initial read.

Evidence takeaway. Evidence from the reviewed source record: FDA K211678 reports standalone testing on 2,412 mammograms acquired on Hologic, GE Healthcare, and Siemens systems, using an independent dataset. Standalone ROC AUC was 0.903 (95% CI 0.889-0.917), with sensitivity 85.74% (95% CI 82.95%-88.53%) and specificity 75.62% (95% CI 73.64%-77.60%); LROC AUC values were 0.781 and 0.792. A separate U.S. retrospective MRMC reader study used 240 mammograms and 12 MQSA-qualified readers: ROC AUC was 0.754 unaided versus 0.805 aided, a 0.051 difference (95% CI 0.027-0.075; p=0.0001). Reader sensitivity and non-cancer recall-rate deltas were exploratory and are distinct from standalone algorithm sensitivity/specificity.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Aid interpreting physicians in detecting, localizing, and characterizing suspicious breast-cancer areas on mammograms from compatible FFDM systems, viewed after the physician completes the initial read.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Second-read adjunct for detection, localization, and characterization; it does not replace complete physician review or clinical judgment.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Screening mammograms from compatible full-field digital mammography systems, received as DICOM images from a PACS or other radiological imaging equipment.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
Visualized lesion maps/heatmaps, finding-level lesion scores from 1-100, and a per-breast abnormality score based on the maximum of the CC and MLO view scores; analysis results are converted to DICOM for storage.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Screening mammography workflow, with the device viewed after the initial physician read.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Physicians interpreting screening mammograms; the target population is women undergoing FFDM screening mammography.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
Use is limited to screening mammograms from compatible FFDM systems and the female screening population described in the packet. The output is adjunctive after the initial read and is not a replacement for complete physician review, clinical judgment, or other patient/image information. DBT is not established in this packet.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA K211678 reports standalone testing on 2,412 mammograms acquired on Hologic, GE Healthcare, and Siemens systems, using an independent dataset. Standalone ROC AUC was 0.903 (95% CI 0.889-0.917), with sensitivity 85.74% (95% CI 82.95%-88.53%) and specificity 75.62% (95% CI 73.64%-77.60%); LROC AUC values were 0.781 and 0.792. A separate U.S. retrospective MRMC reader study used 240 mammograms and 12 MQSA-qualified readers: ROC AUC was 0.754 unaided versus 0.805 aided, a 0.051 difference (95% CI 0.027-0.075; p=0.0001). Reader sensitivity and non-cancer recall-rate deltas were exploratory and are distinct from standalone algorithm sensitivity/specificity.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K211678 reports standalone testing on 2,412 mammograms acquired on Hologic, GE Healthcare, and Siemens systems, using an independent dataset. Standalone ROC AUC was 0.903 (95% CI 0.889-0.917), with sensitivity 85.74% (95% CI 82.95%-88.53%) and specificity 75.62% (95% CI 73.64%-77.60%); LROC AUC values were 0.781 and 0.792. A separate U.S. retrospective MRMC reader study used 240 mammograms and 12 MQSA-qualified readers: ROC AUC was 0.754 unaided versus 0.805 aided, a 0.051 difference (95% CI 0.027-0.075; p=0.0001). Reader sensitivity and non-cancer recall-rate deltas were exploratory and are distinct from standalone algorithm sensitivity/specificity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Standalone Lunit INSIGHT MMG sensitivity: 85.74% (95% CI 82.95%-88.53%) on 2,412 screening mammograms; the separate reader-study cancer-group recall-rate difference was 5.97 percentage points.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

The standalone algorithm endpoint must remain separate from the aided-versus-unaided reader-study delta and ROC AUC.

Reported specificity
Standalone Lunit INSIGHT MMG specificity: 75.62% (95% CI 73.64%-77.60%) on 2,412 screening mammograms; the separate reader-study non-cancer recall-rate difference was -1.46 percentage points.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

This is the standalone algorithm endpoint; reader-study recall, ROC AUC, and LROC AUC are distinct and must not be substituted.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Lunit INSIGHT MMG regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K211678
  • Samplen=2412
  • IndependenceIndependence not established

K211678

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K211678. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Screening mammograms from compatible full-field digital mammography systems, received as DICOM images from a PACS or other radiological imaging equipment.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K211678: Lunit INSIGHT MMG

  2. Routing

    Source context, not route validation: The software receives mammograms from a client image-storage system such as PACS or other radiological equipment, de-identifies DICOM copies, and saves DICOM results to a designated location such as PACS or an X-ray system. Exact interface versions, routing, and local compatibility are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K211678: Lunit INSIGHT MMG

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: Visualized lesion maps/heatmaps, finding-level lesion scores from 1-100, and a per-breast abnormality score based on the maximum of the CC and MLO view scores; analysis results are converted to DICOM for storage.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K211678: Lunit INSIGHT MMG

  5. Viewer/worklist/report

    Unresolved route: Visualized lesion maps/heatmaps, finding-level lesion scores from 1-100, and a per-breast abnormality score based on the maximum of the CC and MLO view scores; analysis results are converted to DICOM for storage.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K211678: Lunit INSIGHT MMG

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The software receives mammograms from a client image-storage system such as PACS or other radiological equipment, de-identifies DICOM copies, and saves DICOM results to a designated location such as PACS or an X-ray system. Exact interface versions, routing, and local compatibility are not established.
  • Exact FDA submission
  • Checked 2026-09-09
Security
Lunit's information security page states the company is ISO/IEC 27001 certified, with ISO 13485 and MDSAP at its manufacturing site. Company-level; the page gives no scope, dates or product controls.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Lunit INSIGHT MMG; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K211678
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Breast.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-11-17
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
12Screened PubMed leads
4Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 12 PubMed and 4 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 12 PubMed and 4 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K211678 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K211678: Lunit INSIGHT MMG

    U.S. Food and Drug Administration - Published 2021-11-17 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Lunit INSIGHT MMG model card (K211678)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K211678

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Lunit Information Security and Medical Device Registration

    Lunit - Accessed 2026-10-25

    Scope: security

Research history

  1. K211678 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23
FDA-cleared K253796

Lunit INSIGHT DBT (V1.2)

Lunit, Inc.

Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-03-26
FDA-cleared K243341

Genius AI Detection 2.0

Hologic, Inc.

Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-07-31

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history